OR WAIT null SECS
October 01, 2020
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.
The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.
September 24, 2020
The facility for early-phase clinical biologics formulation development and drug product fill/finish services will be integrated with an existing Catalent facility nearby.
September 14, 2020
The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers.
September 02, 2020
The companies have signed a definitive agreement to acquire a majority stake of PCI Pharma Services.
September 01, 2020
The facility offers office, production, sampling, and warehouse space and delivers products to all major global markets.
August 31, 2020
The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.
The transaction will give Ionis access to Akcea's pipeline and commercial products, as well as its cash on hand of approximately $390 million.
August 28, 2020
AbCellera’s recent acquisition of the OrthoMab bispecific platform is expected to accelerate antibody product development.
August 26, 2020
Müller + Müller will become part of DWK upon closing in September 2020 and will continue to function under the same name and management.